Feng Yu / Shutterstock.com
The US Court of Appeals for the Federal Circuit decided on June 14 that the two patents involved in a dispute between Biomarin Pharmaceuticals and Genzyme Therapeutic Products are unpatentable due to being obvious.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Biomarin, Genzyme, patent, Pompe’s disease, GAA, PTAB, Patent Trial and Appeal Board